- Home
- AARD vs TLSA Comparison
AARD vs TLSA Comparison
Compare AARD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- TLSA
- Stock Information
- Founded
- AARD 2017
- TLSA 2013
- Country
- AARD United States
- TLSA United Kingdom
- Employees
- AARD N/A
- TLSA N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- AARD Health Care
- TLSA Health Care
- Exchange
- AARD Nasdaq
- TLSA Nasdaq
- Market Cap
- AARD 186.3M
- TLSA 187.0M
- IPO Year
- AARD 2025
- TLSA 2000
- Fundamental
- Price
- AARD $16.08
- TLSA $1.97
- Analyst Decision
- AARD Strong Buy
- TLSA
- Analyst Count
- AARD 7
- TLSA 0
- Target Price
- AARD $31.43
- TLSA N/A
- AVG Volume (30 Days)
- AARD 238.4K
- TLSA 455.3K
- Earning Date
- AARD 11-14-2025
- TLSA 05-06-2025
- Dividend Yield
- AARD N/A
- TLSA N/A
- EPS Growth
- AARD N/A
- TLSA N/A
- EPS
- AARD N/A
- TLSA N/A
- Revenue
- AARD N/A
- TLSA N/A
- Revenue This Year
- AARD N/A
- TLSA N/A
- Revenue Next Year
- AARD N/A
- TLSA N/A
- P/E Ratio
- AARD N/A
- TLSA N/A
- Revenue Growth
- AARD N/A
- TLSA N/A
- 52 Week Low
- AARD $4.88
- TLSA $0.63
- 52 Week High
- AARD $19.58
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- AARD 79.19
- TLSA 53.23
- Support Level
- AARD $10.75
- TLSA $1.90
- Resistance Level
- AARD $14.32
- TLSA $2.18
- Average True Range (ATR)
- AARD 1.07
- TLSA 0.17
- MACD
- AARD 0.58
- TLSA 0.02
- Stochastic Oscillator
- AARD 95.99
- TLSA 46.48
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.